ArticleArquivos de neuro-psiquiatria2022
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
Caio Vinicius de Meira Grava SimioniPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it